In vivo 'purging' of residual disease in CLL with Campath-1H.

Journal article

We assessed the role of human CD52 antibody (Campath-1H) in six patients with chronic lymphocytic leukaemia (CLL) treated to maximal response with purine analogues (fludarabine/deoxycoformycin) in whom persistent leukaemic infiltration of blood and bone marrow had precluded autologous stem cell transplantation. Five patients achieved haematological and histological complete remission following Campath-1H and one had minimal focal residual CLL in a trephine biopsy. Autologous transplantation was performed in two patients without complications and with rapid haemopoietic engraftment. Treatment with Campath-1H may be of value in eradicating residual disease in CLL and may facilitate high-dose therapy in young patients.

Authors: Dyer, M; Kelsey, S; Mackay, H; Emmett, E; Thornton, P

• Publication status: Published
• Journal: British journal of haematology
• Volume: 97
• Issue: 3
• Pages: 669-672
• Publication date: 1997-06-01
• DOI: 10.1046/j.1365-2141.1997.1062924.x
• EISSN: 1365-2141
• ISSN: 0007-1048
• Language: English
• Keywords: Adult; Neoplasm, Residual; Vidarabine; Leukemia, Lymphocytic, Chronic, B-Cell; Female; Middle Aged; Pentostatin; Humans; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antibodies, Monoclonal; Male